补肺益肾汤联合舒利迭治疗肺肾亏虚型慢性阻塞性肺疾病临床研究
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563

基金项目:

河南省科学技术厅项目(162102310445)


Clinical Study on Bufei Yishen Tang Combined with Seretide for COPD of Lung and Kidney Depletion Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察补肺益肾汤联合舒利迭治疗肺肾亏虚型慢性阻塞性肺疾病的临床疗效。方法:将80 例肺肾亏虚型慢性阻塞性肺疾病患者按随机数字表法分为研究组和对照组各40 例。2 组均给予常规西医治疗,对照组给予舒利迭治疗,研究组在对照组基础上联合补肺益肾汤治疗,均治疗4 周。比较2 组临床疗效,评价改良呼吸困难指数(mMRC) 评分、圣乔治医院呼吸问题调查问卷(SGRQ) 评分变化,检测血清白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)、和肽素(Copeptin) 及高迁移率族蛋白B1 (HMGB1) 变化。结果:研究组总有效率为95.00%,高于对照组77.50%,差异有统计学意义(P<0.05)。治疗后,2 组mMRC 评分、活动评分、症状评分、影响评分较治疗前降低(P<0.05),且研究组各项评分均低于对照组(P<0.05)。治疗后,对照组第1 秒用力呼气容积占预计值百分比(FEV1%) 较治疗前升高(P<0.05);研究组第1 秒用力呼气容积(FEV1)、FEV1%、FEV1/FVC 较治疗前升高,且显著高于对照组,差异均有统计学意义(P<0.05)。治疗后,2 组血清IL-1β、TNF-α、Copeptin、HMGB1 水平均较治疗前降低,且研究组血清IL-1β、TNF-α、Copeptin、HMGB1 水平均低于对照组,差异均有统计学意义(P<0.05)。结论:补肺益肾汤联合舒利迭可显著改善肺肾亏虚型COPD 患者的活动耐力、生活质量,改善肺功能,降低血清IL-1β、TNF-α 水平及血清Copeptin、HMGB1 的表达。

    Abstract:

    Abstract: Objective: To observe the clinical effect of the therapy of Bufei Yishen tang combined with seretide on the treatment of chronic obstructive pulmonary disease of lung and kidney depletion type. Methods: A total of 80 chronic obstructive pulmonary disease patients of lung and kidney depletion type were divided into the study group and the control group according to the random number table method,40 cases in each group. Both groups were given conventional western medicine treatment,and the control group was additionally treated with seretide;the study group was additionally treated with Bufei Yishen tang based on the treatment of the control group. The treatment lasted for four weeks. The clinical effect was compared between the two groups;the changes in the scores of modified Medical Research Council(mMRC) and the St. George's Respiratory Questionaire(SGRQ) were evaluated; the changes in the levels of interleukin- 1β(IL- 1β), tumor necrosis factor- α(TNF- α), Copeptin and high mobility group B1(HMGB1) in serum were detected. Results: The total effective rate was 95.00% in the study group, higher than that of 77.50% in the control group, the difference being significant(P<0.05). After treatment, the mMRC scores, the activity scores, symptom scores and influence scores were decreased in the two groups when compared with those before treatment(P<0.05),and the above scores in the study group were lower than those in the control group(P<0.05). After treatment,the percentage of forced expiratory volume in the first second to the predicted value(FEV1% ) in the control group was increased when compared with that before treatment(P< 0.05); the exhalation volume in the first second(FEV1), FEV1% and FEV1/FVC in the study group were increased when compared with those before treatment, and were significantly higher than those in the control group, differences being significant(P<0.05). After treatment,the levels of IL-1β,TNF-α,Copeptin and HMGB1 in serum in the two groups were decreased when compared with those before treatment,and the above levels in the study group were lower than those in the control group, differences being significant(P<0.05). Conclusion: The therapy of Bufei Yishen tang combined with seretide can significantly improve activity endurance,quality of life,lung function,and reduce the levels of IL-1β,TNF-α, Copeptin and HMGB1 in serum in COPD patients with lung and kidney deficiency.

    参考文献
    相似文献
    引证文献
引用本文

杨秀青,赵璐.补肺益肾汤联合舒利迭治疗肺肾亏虚型慢性阻塞性肺疾病临床研究[J].新中医,2021,53(5):91-95

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-03-15
  • 出版日期: